The health-related quality-of-life (HRQOL) implications of advanced metastatic prostate cancer are variable.
There are several different HRQOL instruments that measure domains germane to patients with advanced metastatic disease. The burden of prostate cancer is inversely related to the magnitude of HRQOL declines. Treatment with androgen deprivation therapy commonly results in HRQOL declines that have served as the impetus for intermittent therapy. Conversely, chemotherapeutic agents have been associated with improvements in functional status for men with castrate-resistant disease. Emerging therapies may result in significant HRQOL improvements in this population, and careful prospective evaluation of patient-reported outcomes will be required.
Written by:
Resnick MJ, Penson DF. Are you the author?
Department of Urologic Surgery, Center for Surgical Quality and Outcomes Research, Vanderbilt University, Nashville, TN, USA; VA Tennessee Valley Geriatric Research Education and Clinical Center (GRECC), 1310 24th Avenue South, Nashville, TN 37212-2637, USA.
Reference: Urol Clin North Am. 2012 Nov;39(4):505-15.
doi: 10.1016/j.ucl.2012.07.007
PubMed Abstract
PMID: 23084527
UroToday.com Prostate Cancer Section
